![]() ![]() “This new capital will jump-start the highly anticipated launch of Vivally, which sets a new standard for OAB care,” said Jill Schiaparelli, MBA, Avation co-founder and CEO. The system also demonstrated improved patient quality of life.Īvation plans to launch the system - available with a prescription - in key markets this spring. It offers use earlier in the care pathway and demonstrated the ability to reduce daily void, incontinence and urgency episodes. Notably, Vivally requires no surgery and no drugs, unlike other implantable neuromodulation approaches for bladder treatment. Worn on the ankle, Vivally only requires 30-minute therapy sessions as infrequently as once per week. This ensures optimal, customized therapeutic output in a real-time, closed-loop operation. The #medicaldevice system uses proprietary algorithms and electromyographic sensors.Īvation designed Vivally to detect and calibrate the level of energy delivered to the tibial nerve during stimulation. Vivally, a non-invasive, FDA-cleared wearable #neurostimulation system delivers closed-loop, autonomously adjusted electrical stimulation to treat patients with urge #urinaryincontinence (UUI) and urinary urgency caused by #overactivebladder (OAB) syndrome. The Columbus, Ohio-based #MedTech #startup plans to use funds to support the U.S. ![]() Existing investors Arboretum Ventures, Tonkawa, Medtronic, and Avestria Ventures participated as well. Other new investors included Angelini Ventures, JobsOhio Growth Capital Fund and more. New investors ShangBay Capital and Asahi Kasei led the round. “This new indication for Proclaim XR will drive meaningful change in the treatment of pain associated with diabetic peripheral neuropathy and will be an important tool for physicians and patients in managing this debilitating condition.”įDA approves Abbott's spinal cord stimulation system for diabetic peripheral neuropathyĪvation Medical Raises $22M for Closed-Loop Wearable Neuromod Tech:Īvation Medical announced today that it raised $22 million in a Series C financing round to support its wearable peripheral #neuromodulation technology. “As a leader in diabetes care, Abbott is intimately familiar with the challenges people with diabetes encounter daily,” said Pedro Malha, VP of #Neuromodulation at Abbott. ![]() They can also program the device using the NeuroSphere technology. Users can now control their therapy through the Apple device. The battery lasts up to 10 years at low-dose settings, too.Ībbott conducted a successful minimally invasive trial for Proclaim XR in tandem with Apple devices. It now offers DPN patients relief from chronic pain through low doses of stimulation. Proclaim XR initially received FDA approval for treating chronic pain in 2019. Patients can only receive symptom management and behavioral modifications to mitigate further nerve damage from high glucose levels. NeuroSphere, a connected care app, allows people to communicate with a physician and receive treatment adjustments remotely.Ĭurrently, no disease-modifying treatments for DPN exist, Abbott said in a news release. Users of Proclaim XR can also use Abbott’s NeuroSphere virtual clinic. These patients need #medicaldevice alternatives to traditional treatment approaches like oral medication. The Proclaim XR SCS #MedTech system offers relief to patients with DPN, a debilitating complication of #diabetes. FDA Approves Abbott’s Spinal Cord Stimulation System for Diabetic Peripheral Neuropathy:Ībbott announced that the FDA approved its #SpinalCordStimulation system for treating painful diabetic peripheral neuropathy (DPN). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |